Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Dutch Initiative on Crohn and Colitis, Vince B. C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen-de Jong, Mark Lowenberg, Nanne K. de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M. Jansen, Alexander G. L. Bodelier, Rachel L. West, Annemarie C. de Vries, Jeoffrey J. L. Haans, Dirk de Jong, Frank Hoentjen, Marieke J. Pierik*
Duik in de onderzoeksthema's van 'Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment'. Samen vormen ze een unieke vingerafdruk.